Adding lenalidomide and nivolumab to the usual drugs for primary CNS lymphoma

Official title: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether two added drugs can help treat lymphoma in the brain and spinal cord.

Read our full plain-language summary

What the trial team says

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents to improve response. This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction).

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT04609046
Stage of testing
Phase 1
Conditions studied
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Where it is running

This trial lists 55 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.